HPCwire: Gene Network Sciences Creates Quant Finance Spin-Off

The Leading Source for Global News and Information Covering the Ecosystem of High Productivity Computing

HPCwire >> Industry >> Financial Services

November 25, 2008

Gene Network Sciences Creates Quant Finance Spin-Off

CAMBRIDGE, Mass., Nov. 25 -- Gene Network Sciences, Inc. (GNS) today announced that it has created a subsidiary company, Fina Technologies, Inc. (Fina) to leverage its proprietary Reverse Engineering, Forward Simulation (REFS) software platform in a new arena -- that of quantitative financial trading and e-commerce. REFS was originally developed to rapidly process raw clinical and genomics data to identify drug targets, biomarkers and drug and disease mechanisms for disease categories such as cancer, diabetes and inflammation, and has been used by GNS in partnership with leading pharmaceutical companies and clinical research organizations such as Johnson & Johnson, Pfizer, Novartis AG, Biogen Idec, UCSF Cancer Center, and Jackson Laboratories for these purposes.

"Hidden complex networks govern everything from human diseases to financial markets and the internet, making reliable predictions impossible," said Colin Hill, President and CEO of GNS and Chairman of the Board of Fina: "It is only today that terabytes of data, on-demand supercomputing, and next-generation artificial intelligence software have converged to enable the uncovering of such networks, and prediction of their behavior, such as predicting how a combination of two cancer drugs would affect the size of a tumor in a cancer patient with a particular DNA sequence."

GNS, who developed their proprietary REFS technology over the past eight years, uses supercomputers to rapidly accelerate the processing of raw data into meaningful biomedical outcomes. To date, this REFS software has been used to probe and analyze how genes and proteins interconnect in a complex web with the goal of developing better drugs. Today, GNS has launched Fina Technolgies (http://www.finatechnologies.com) to monetize their REFS technology in the e-commerce and financial trading markets, while remaining focused on their original drug development mission.

Fina Technologies has obtained from GNS an exclusive license to certain non-biological applications of REFS, such as quantitative finance, e-commerce, insurance, and fraud detection. "Fina will use REFS to create quantitative trading algorithms and deliver business solutions for a new class of data intensive problems," said Josh Holden, CEO of Fina. "After spending 13 years trading on Wall Street, this is the first tool I've seen that automates the discovery of complex and evolving relationships from massive amounts of data, leading to more reliable and more profitable trading strategies."

Fina Technologies is supported in their efforts through an initial round of investment led by Reed Elsevier Ventures, the venture arm of the multibillion dollar Anglo-Dutch media conglomerate Reed Elsevier, owner of such assets as Lexis-Nexis, and by a Board of Directors steeped in finance and e-commerce. In addition to Colin Hill, Co-founder and President and CEO of GNS, the Board of Fina includes Bill Trenchard, founder of Jump Networks, a start-up company that developed the world's first online calendaring system, which was sold to Microsoft for $50 million in 1999, and who is a current Board member of LiveOps, another company he founded. Also on the Board of Fina are Kevin Brown, Partner at Reed Elsevier Ventures; and Robert Maroney, Investment Manager at Connecticut Investments, LLC.

About REFS

Reverse Engineering/Forward Simulation (REFS) is a technology that systematically turns multiple layers of data into an unprecedented view of complex systems as a "whole," without requiring previous knowledge of the structure of the system. REFS begins with raw data and rapidly performs billions upon billions of calculations using supercomputers to determine how the individual components in the system interact with one another (Reverse Engineering). These computer-assembled models are then simulated using billions of in silico queries (Forward Simulation) to discover the highest-impact components and to predict outcomes for previously unseen scenarios.

About Gene Network Sciences

Founded in 2000, Gene Network Sciences (http://www.gnsbiotech.com) is a leader in biosimulation with its ability to derive molecular mechanisms of drugs and diseases directly from molecular profiling and clinical data without any a priori knowledge. Headquartered in Cambridge, Massachusetts, GNS uses its REFS (reverse engineering and forward simulation) technology in pharmaceutical and clinical settings to rapidly turn complex and heterogeneous data sets into cell and organ-level computer models of disease biology, drug efficacy and drug safety. These models simulate mechanisms of disease and the clinical performance of drug candidates. By discovering how and why specific drug candidates impact human biology, GNS technology enables the rapid development of breakthrough drug and diagnostic products.

-----

Source: Gene Network Sciences

Article Tools

Share Options

(Digg, Technorati, more)

Subscribe

Subscribe to HPCwire

Discussion

There are 0 discussion items posted.

Join the Discussion

You must be a registered user in order to comment on HPCwire stories.

Members enjoy:

	Access to Special Content, including Podcasts, Webcasts, and Whitepapers and more!
	Ability to take an active role in the discussions that are shaping the HPC technology discipline!
	Special offers available only to HPCwire members!

Become a Registered User Today!

Registered Users Log in Here to Comment

Email Address:	Password (case sensitive)

Remember me	Forgot Password?

RSS Feeds

Feeds by Topic

Feeds by Industry

Feeds by Content Type

Feature Articles

The Week in Review

C-DAC announces plans for a petaflop system; IBM researchers are working on vertical integration techniques to extend Moore's Law another 15 years. We recap those stories and more in our weekly wrapup.
Read More...

Moscow State University Supercomputer Has Petaflop Aspirations

The Moscow State University supercomputer, Lomonosov, has been selected for a high-performance makeover, with the goal of tripling its processing power to achieve petaflop-level performance in 2010. T-Platforms, who developed and manufactured the supercomputer, is the odds-on favorite to lead the project.
Read More...

Intel Ups Performance Ante with Westmere Server Chips

Right on schedule, Intel has launched its Xeon 5600 processors, codenamed "Westmere EP." The 5600 represents the 32nm sequel to the Xeon 5500 (Nehalem EP) for dual-socket servers. Intel is touting better performance and energy efficiency, along with new security features, as the big selling points of the new Xeons.
Read More...

Read more HPCwire features...

Top Headlines

Australia Commissions Cray Supercomputer

Mar 19 | OfficialWire | New super to support intelligence work Down Under. Read more...

Intel Partners See 'Easy' Upgrade Path With Xeon 5600 Chips

Mar 18 | ChannelWeb | Westmere parts already showing up in HPC machines. Read more...

AMD: OEMs primed for Opteron 6100s

Mar 17 | The Register | But what about the tier ones? Read more...

Arrival of the Desktop Supercomputer

Mar 17 | Cadalyst Magazine | A new generation of workstations is changing the nature of technical computing. Read more...

Scheduling HPC In The Cloud

Mar 17 | Linux Magazine | Latest iteration of Sun Grid Engine able to tap into Cloud. Read more...

Read more headlines...

Featured Whitepapers

Virtualization for Aggregation And The vSMP Architecture™

Jan 12 | | In-depth look at vSMP Foundation server virtualization technology, technical implementation, use cases and capabilities. The technical whitepaper provides an architectural overview and details on the three vSMP Foundation products: vSMP Foundation for SMP, vSMP Foundation for Cluster and vSMP Foundation for Cloud.

Copper Cable Technologies for High Performance Computing

Jan 18 | | This white paper discusses Gore’s copper cable assemblies, and how they continue to exceed the standards for providing reliable, cost-effective solutions for high-performance computer applications.

View the White Paper Library

Multimedia

Webcast: Virtualized Data Center Roundtable

Join this online panel discussion for live Q&A with leading industry experts, analysts, and end-users to discuss the latest innovations, best practices, barriers to implementation, and measurable benefits of server virtualization with a particular focus on today's real world solutions.

Webcast: Watch SC09 Birds of a Feather Video: Scalable Fault-Tolerant HPC Supercomputers

Learn about scalable fault-tolerant architectures and examples of energy efficient and scalable supercomputing clusters using dual QDR InfiniBand to combine capacity computing with network failover capabilities with the help of programming languages such as MPI and a robust Linux cluster management package.

Webcast: High Performance Computing for a Smarter Planet

LIVE@SCO9: The IBM team discusses new innovations in hardware, software and services that help clients better understand their workloads and get insight from their R&D efforts. Technology demonstrations include the soon-to-be-released Power7 HPC processor, the DCS990 system with 2.4 petabytes of storage, the xCAT management tool, secure HPC cloud computing and more. Winners of two HPCwire Readers' and Editors’ Choice Awards! Take the IBM virtual tour at SC09 or more information go online to: http://www-03.ibm.com/systems/deepcomputing/sc09.html